Among others, the combination of conventional chemotherapeutic drugs, such as paclitaxel, sorafenib or gemcitabine with liposomal C6-ceramide (acting at the level of PI3K/Akt/mTOR, essential to CSC proliferation and survival [29]), presented superior efficacy relative to monotherapies in ovarian [50], breast [51] and pancreatic [52] cancer mouse models. The gene discussed is MTOR; the disease is cancer.